AKERO THERAPEUTICS INC (AKRO)
US00973Y1082 - Common Stock
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such...
Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.
/PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements...
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
Commit To Purchase Akero Therapeutics At $15, Earn 16% Using Options
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led...
Investors Bag AKRO Even Cheaper Than Its Secondary Stock Offering
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Akero Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...
Notable Monday Option Activity: AKRO, VSCO, THO
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning!
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%)
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data...
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.
Liver disease drug developers rise after Gilead-CymaBay deal (NASDAQ:GILD)
Gilead&#39;s (GILD) acquisition of CymaBay Therapeutics CBAY) boosts liver disease-focused drug developers, leading to notable gains in their stock prices. Read more here.
Oversold Conditions For Akero Therapeutics (AKRO)
NASH drug developers drop after trial win for Lilly drug
Companies focused on NASH drugs drop as Eli Lilly's (LLY) weight loss drug, tirzepatide, hits main goal in a mid-stage trial for the liver disease. Read more here.
NASH drug developers drop after trial win for Lilly drug (NASDAQ:SGMT)
Companies focused on NASH drugs drop as Eli Lilly's (LLY) weight loss drug, tirzepatide, hits main goal in a mid-stage trial for the liver disease. Read more here.